Viferon-3 candles 1000000me №10

Mechanism of action

The preparation of human recombinant Interferon alfa-2b.
It has antiviral, immunomodulatory and antiproliferative effects. Under the influence of interferon in the body, the activity of natural killer cells, T-helper cells, cytotoxic T-lymphocytes, phagocytic activity, B-lymphocyte differentiation intensity, and expression of MHC type I and II antigens increase.
The drug also directly inhibits the replication and transcription of viruses, chlamydia.
Damage to cell membranes, observed during the development of an infectious process, is the reason for the decrease in the antiviral activity of interferon. Tocopherol acetate and Ascorbic acid, which are part of the drug Viferon, are membrane-stabilizing components, antioxidants, in combination with which the antiviral activity of recombinant interferon alpha-2b increases 10-14 times. In addition, the immunomodulatory effect of interferon on T- and B-lymphocytes is enhanced, the content of immunoglobulin E is normalized, there are no side effects (fever, fever, influenza-like phenomena) arising from the parenteral administration of interferon preparations.
It has been established that when using Viferon for 2 years, antibodies that neutralize the antiviral activity of recombinant interferon alpha-2b are not formed.
The use of the drug Viferon can significantly reduce the course dose and the duration of courses of treatment with antibiotics, hormones and cytotoxic drugs.
Features of the introduction of the dosage form provide long-term circulation in the blood of interferon alfa-2b.

12 h after rectal administration of Viferon, a decrease in the level of interferon in the blood serum is observed, which necessitates its repeated administration.

Indications and usage

- as part of complex therapy of infectious and inflammatory diseases in newborns (including premature infants) children: SARS, pneumonia (bacterial, viral, chlamydia), meningitis, sepsis, specific intrauterine infection (chlamydia, herpes infections, cytomegalovirus infection, enteroviral infections, visceral candidiasis, mycoplasmosis);
- as part of complex therapy of chronic viral hepatitis B, C, D in children, as well as in the treatment of chronic viral hepatitis with a pronounced degree of activity and cirrhosis of the liver using plasma exchange and hemosorption;
- in pregnant women with urogenital infection (chlamydia, genital herpes, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellezis, human papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) as an interferonorrhagic agent
- treatment of herpetic lesions of the skin and mucous membranes (for ointment).

Dosage and administration

Viferon suppositories are administered rectally.
In the complex treatment of infectious and inflammatory diseases newborn (including premature) children appoint Viferon-1.
Newborn (including premature) babies with gestational age of more than 34 weeks the drug is prescribed 1 suppository 2 times / day with an interval of 12 hours.
Premature babies with gestational age less than 34 weeks - 1 suppository 3 times / day with an interval of 8 hours. The course of treatment is 5 days.
The recommended number of courses Viferon with various infectious and inflammatory diseases in newborns (including premature) children: ARVI - 1 course; pneumonia bacterial - 1-2 courses, viral - 1 course, chlamydia - 1 course; sepsis - 2-3 courses; meningitis - 1-2 courses; herpes infections - 2 courses; enterovirus infection - 1-2 courses; cytomegalovirus infection - 2-3 courses; mycoplasmosis - 2-3 courses. The break between courses is 5 days. According to clinical indications, Viferon therapy can be continued.

prescribed Viferon-2 1 suppository 2 times a day with an interval of 12 hours for 5 days.

Viferon is prescribed at the rate of 3 million IU interferon / m² body surface / day. The drug is prescribed in 2 suppositories / day with an interval of 12 hours daily for 10 days; then 2 suppositories per day are administered with an interval of 12 hours 3 times a week every other day for 6-12 months.
In chronic hepatitis, a pronounced degree of activity and cirrhosis of the liver before plasmapheresis and / or hemosorption are prescribed 2 suppositories per day with an interval of 12 hours daily for 14 days. Children under 7 years old appoint Viferon-1, children over 7 years old Viferon-2.

designate Viferon-1, 2 suppositories / day with an interval of 12 hours every other day. The course of treatment is 10 suppositories.
From 35 weeks to delivery prescribed Viferon-2, 2 suppositories / day with an interval of 12 hours daily. The course of treatment is 5 days.
A total of 7 courses are prescribed for 12 weeks. The break between courses is 7 days. The duration of treatment is determined by the dynamics of clinical and laboratory parameters.

prescribed at the onset of the first symptoms of herpetic lesions of the skin and mucous membranes and in the first 2-3 days of herpes recurrence of various localization and continue for 5-7 days.
Ointment is applied with a thin layer to the lesions and rubbed gently 2-3 times / day.

Adverse reactions

When applied according to indications in recommended doses, side effects were not detected.

Contraindications

Hypersensitivity to cocoa butter.

Pregnancy and breastfeeding

Perhaps the use of Viferon during pregnancy according to indications.

Special notes

For the treatment of a wide range of infectious and inflammatory diseases, Viferon can be used in combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs.
There is evidence of the effectiveness of the drug Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpes infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children over 1 year old; viral hepatitis in adults, SARS, influenza, bronchial asthma, juvenile rheumatoid arthritis; meningeal form of tick-borne encephalitis; prostatitis of various etiologies; purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephritis.

Storage conditions

The drug should be stored in a dry, dark place at a temperature of from 2 ° to 8 ° C.